Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Ann Hepatobiliary Pancreat Surg. 2018 Feb;22(1):19-26. English. Original Article. https://doi.org/10.14701/ahbps.2018.22.1.19
Hwang S , Ahn CS , Kim KH , Moon DB , Ha TY , Song GW , Jung DH , Park GC , Lee SG .
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. shwang@amc.seoul.kr
Abstract

Backgrounds/Aims

Long-term immunosuppression regimens after liver transplantation (LT) are rarely reported in detail. We aimed to provide information on actual long-term immunosuppression regimens through this cross-sectional study.

Methods

Our institutional LT database was searched for adult patients who underwent primary LT operation from 2000 to 2016. We identified 3620 live recipients with actual information on immunosuppressive agent use for 1–17 years.

Results

The study cohort was divided into 7 groups according to posttransplantation period. The immunosuppressive agents used at the cross-sectional review period were tacrolimus in 2884 (79.7%), cyclosporine in 445 (12.3%), mycophenolate mofetil in 2007 (55.4%), and everolimus in 138 (3.8%) recipients. There was no marked difference in immunosuppressive agent use according to pretransplantation liver malignancy or type of LT operation. Tacrolimus, cyclosporine, mycophenolate mofetil, and everolimus were used in 97.4%, 1.8%, 60.9%, and 9.2%, respectively, in the year 2 group; 94.1%, 3.9%, 51.6%, and 8.3%, respectively, in the year 3 group; 87.3%, 8.4%, 68.9%, and 4.8%, respectively, in the year 4–5 group; 78.2%, 12.9%, 64.6%, and 3.0%, respectively, in the year 6–7 group; 76.9%, 10.8%, 58.8%, and 2.4%, respectively, in the year 8–10 group; 66.7%, 22.4%, 43.4%, and 1.5%, respectively, in the year 11–15 group; and 73.8%, 15.4%, 32.9%, and 1.7%, respectively, in the year ≥15 group.

Conclusions

Tacrolimus and mycophenolate mofetil are the primary immunosuppressive agents after LT, and the indications for everolimus have started to increase at our institution. We believe our results will help establish tailored long-term immunosuppression regimens.

Copyright © 2019. Korean Association of Medical Journal Editors.